Germany
Japan
United Kingdom
China
ALK mouse monoclonal antibody, clone OTI1A4
| Applications | IHC, LMNX, WB |
| Reactivities | Human, Mouse, Rat |
| Conjugation | Unconjugated |
Antibodies
.jpg?d=110x100 "User supplied image")
Rabbit monoclonal anti-Sox2 Antibody, clone OTIR102D11
| Applications | WB |
| Reactivities | Human, Mouse, Rat |
| Conjugation | Unconjugated |
Rabbit monoclonal anti-Sox2 Antibody, clone OTIR094F2
| Applications | WB |
| Reactivities | Human, Mouse, Rat |
| Conjugation | Unconjugated |
Rabbit monoclonal anti-PD-L1 Antibody, clone OR-5E4
| Applications | WB |
| Reactivities | Human |
| Conjugation | Unconjugated |
Rabbit monoclonal anti-PD-L1 Antibody, clone OR-5E4
| Applications | WB |
| Reactivities | Human |
| Conjugation | Unconjugated |
Rabbit monoclonal anti-Sox2 Antibody, clone OTIR102D11
| Applications | WB |
| Reactivities | Human, Mouse, Rat |
| Conjugation | Unconjugated |
USD 420.00
In Stock
Mouse anti-PROM1 (CD133) monoclonal antibody
| Applications | WB |
| Reactivities | Human |
| Conjugation | Unconjugated |
Anti-LGR5 mouse mAb, clone OTI2A2, bionylated
| Applications | WB |
| Reactivities | Human, Mouse |
| Conjugation | Biotin |
Mouse Monoclonal ApoE4 Antibody (4E4)
| Applications | WB |
| Reactivities | Human |
| Conjugation | Unconjugated |
USD 479.00
2 Weeks
USD 399.00
In Stock
USD 379.00
In Stock
USD 428.00
In Stock
USD 379.00
In Stock
Rabbit monoclonal anti-ST13 Antibody, clone OTIR191G8
| Applications | WB |
| Reactivities | Human, Mouse, Rat |
| Conjugation | Unconjugated |
TGF beta 1 (TGFB1) mouse monoclonal antibody, clone TB21, Azide Free
| Applications | ELISA, FN, IHC, WB |
| Reactivities | Human, Sheep |
| Conjugation | Unconjugated |
ZCCHC24 mouse monoclonal antibody, clone OTI2E1 (formerly 2E1)
| Applications | WB |
| Reactivities | Human, Mouse, Rat |
| Conjugation | Unconjugated |
USD 750.00
In Stock
Active filters
Category
-
Antibodies
- Primary Antibodies
Reactivities
- Human
Applications
- WB
Clonalities
- Monoclonal
Filter by
Target Symbol
- VSNL1 (271)
- ALK (268)
- KLK8 (241)
- MAP2K1 (202)
- CD4 (201)
- TP53 (193)
- CDKN2A (172)
- PGR (161)
- NME1 (158)
- ERCC1 (153)
- PDCD1 (153)
- MAP2K3 (150)
- JUN (148)
- GLI1 (144)
- CTAG1B (131)
- GADD45G (130)
- KRT19 (130)
- NBN (126)
- LIPG (125)
- OTC (125)
- ERBB2 (123)
- ABCB1 (120)
- CTNNB1 (119)
- CD68 (118)
- MSMB (117)
- HAVCR2 (115)
- CD5 (113)
- PECAM1 (111)
- PIK3C2A (110)
- EGFR (109)
- VIM (109)
- CD274 (108)
- NUMB (106)
- CD99 (105)
- MDM2 (101)
- CFI (100)
- ADIPOQ (99)
- NKX3-1 (98)
- PCNA (98)
- TOP2A (96)
- MAPK13 (95)
- UBE2E3 (95)
- AFP (93)
- L1CAM (93)
- EPCAM (92)
- SENP2 (90)
- VWF (90)
- CD80 (89)
- MLANA (88)
- KRT20 (86)
- LGALS3 (85)
- PNMT (85)
- TYMS (84)
- APP (81)
- MDM4 (80)
- MIEN1 (80)
- BRAF (77)
- TACC2 (75)
- PROCR (71)
- BHLHE41 (70)
- CD27 (70)
- FGF21 (70)
- MLH1 (70)
- SPG7 (70)
- UBA52 (70)
- CD44 (68)
- MKI67 (68)
- NKX2-1 (67)
- BCL2 (66)
- CD33 (66)
- NCAM1 (66)
- PDCD1LG2 (66)
- TG (66)
- AFAP1 (65)
- BCL10 (65)
- CNOT4 (65)
- F13A1 (65)
- LRATD2 (65)
- SLA2 (65)
- SNAI2 (65)
- AKT1 (64)
- ALDH1L1 (64)
- MGMT (64)
- RTRAF (64)
- SQSTM1 (64)
- TNFRSF8 (63)
- FCGR2A (61)
- PIK3CG (61)
- ABAT (60)
- BSG (60)
- BTLA (60)
- CCT8L2 (60)
- IDO1 (60)
- LOX (60)
- LPL (60)
- MIOX (60)
- PARVA (60)
- PSMC3 (60)
- SDR9C7 (60)
- ZFP36 (60)
Antibody Hosts
Isotypes
- IgG1 (41768)
- IgG2a (10494)
- IgG2b (9404)
- IgG (928)
- IgG1, kappa (262)
- IgG3 (185)
- IgG, kappa (106)
- IgM (58)
- IgG2a, kappa (55)
- IgG2b, kappa (50)
- IgG2c (15)
- IgM, kappa (12)
- IgG1, lambda (8)
- IgG3, kappa (7)
- IgG fraction (1)
- IgG1/IgK (1)
- IgG2 (1)
- IgG2, alpha (1)
- IgG2, kappa (1)
- IgG2b, lambda (1)
- IgG3/IgG1 (1)
- IgG4 (1)
- cocktail (1)
Conjugates
Carrier-free
Knockout (KO) Validation
Modifications
- This chimeric rabbit antibody was made using the variable domain sequences of the original Mouse IgG1 format, for improved compatibility with existing reagents, assays and techniques. (32)
- Phospho-specific (15)
- This chimeric rabbit antibody was made using the variable domain sequences of the original Mouse IgG2a format, for improved compatibility with existing reagents, assays and techniques. (12)
- This chimeric rabbit antibody was made using the variable domain sequences of the original murine IgG1 format, for improved compatibility with existing reagents, assays and techniques. (9)
- This chimeric rabbit antibody was made using the variable domain sequences of the original Human IgG1 format, for improved compatibility with existing reagents, assays and techniques. (6)
- This chimeric rabbit antibody was made using the variable domain sequences of the original Mouse IgG2b format, for improved compatibility with existing reagents, assays and techniques. (4)
- This chimeric rabbit antibody was made using the variable domain sequences of the original murine IgG2a format, for improved compatibility with existing reagents, assays and techniques. (4)
- This full-length, chimeric rabbit antibody was made using the variable domain sequences of the original Human scFv format, for improved compatibility with existing reagents, assays and techniques. (4)
- Modification (3)
- NOT FOR THERAPEUTIC USE - This is a research-grade biosimilar. (3)
- NOT FOR THERAPEUTIC USE - This is a research-grade biosimilar. This is a chimeric antibody created for improved compatibility with existing reagents, assays and techniques. (3)
- This full-length, chimeric rabbit antibody was made using the variable domain sequences of the original Mouse scFv format, for improved compatibility with existing reagents, assays and techniques. (3)
- This full-length, reformatted mouse antibody was made using the variable domain sequences of the original Mouse scFv format, for improved compatibility with existing reagents, assays and techniques. (3)
- This reformatted mouse antibody was made using the variable domain sequences of the original Mouse IgG2a format, for improved compatibility with existing reagents, assays and techniques. (3)
- This chimeric mouse antibody was made using the variable domain sequences of the original Human IgG1 format, for improved compatibility with existing reagents, assays and techniques. (2)
- This chimeric rabbit antibody was made using the variable domain sequences of the original Rat IgG2a format, for improved compatibility with existing reagents, assays and techniques. (2)
- This full-length, chimeric mouse antibody was made using the variable domain sequences of the original Human scFv format, for improved compatibility with existing reagents, assays and techniques. (2)
- This full-length, reformatted human antibody was made using the variable domain sequences of the original Human scFv format, for improved compatibility with existing reagents, assays and techniques. (2)
- This is a chimeric antibody created for improved compatibility with existing reagents, assays and techniques. (2)
- This reformatted mouse antibody was made using the variable domain sequences of the original Mouse IgG format, for improved compatibility with existing reagents, assays and techniques. (2)
- NOT FOR THERAPEUTIC USE - This is a research-grade biosimilar. This chimeric rabbit antibody was made using the variable domain sequences of the original Human IgG1 format, for improved compatibility with existing reagents, assays and techniques. (1)
- NOT FOR THERAPEUTIC USE - This is a research-grade biosimilar. This chimeric rabbit antibody was made using the variable domain sequences of the original human IgG1 format, for improved compatibility with existing reagents, assays and techniques. (1)
- This chimeric human antibody was made using the variable domain sequences of the original Mouse IgG2a format, for improved compatibility with existing reagents, assays and techniques. (1)
- This chimeric mouse antibody was made using the variable domain sequences of the original Human format, for improved compatibility with existing reagents, assays and techniques. (1)
- This chimeric murine antibody was made using the variable domain sequences of the original Human IgG1 format, for improved compatibility with existing reagents, assays and techniques. (1)
- This chimeric rabbit antibody was made using the variable domain sequences of the original Human format, for improved compatibility with existing reagents, assays and techniques. (1)
- This chimeric rabbit antibody was made using the variable domain sequences of the original Human IgG4 format, for improved compatibility with existing reagents, assays and techniques. (1)
- This chimeric rabbit antibody was made using the variable domain sequences of the original Mouse IgG format, for improved compatibility with existing reagents, assays and techniques. (1)
- This chimeric rabbit antibody was made using the variable domain sequences of the original Mouse IgG2 format, for improved compatibility with existing reagents, assays and techniques. (1)
- This chimeric rabbit antibody was made using the variable domain sequences of the original Mouse IgG3 format, for improved compatibility with existing reagents, assays and techniques. (1)
- This chimeric rabbit antibody was made using the variable domain sequences of the original Mouse IgM format, for improved compatibility with existing reagents, assays and techniques. (1)
- This chimeric rabbit antibody was made using the variable domain sequences of the original Mouse scFv antibody fragment format, for improved compatibility with existing reagents, assays and techniques. (1)
- This chimeric rabbit antibody was made using the variable domain sequences of the original Rat IgG2b format, for improved compatibility with existing reagents, assays and techniques. (1)
- This chimeric rabbit antibody was made using the variable domain sequences of the original murine IgG2b format, for improved compatibility with existing reagents, assays and techniques. (1)
- This chimeric rabbit antibody was made using the variable domain sequences of the original rat IgG2b format, for improved compatibility with existing reagents, assays and techniques. (1)
- This full-length, chimeric mouse antibody was made using the variable domain sequences of the original Chicken scFv format, for improved compatibility with existing reagents, assays and techniques. (1)
- This full-length, chimeric rabbit antibody was made using the variable domain sequences of the original Chicken scFv format, for improved compatibility with existing reagents, assays and techniques. (1)
- This is a chimeric mouse antibody, based on the original rat IgG2b format, created for improved compatibility with existing reagents, assays and techniques. (1)
- This reformatted mouse antibody was made using the variable domain sequences of the original Mouse scFv antibody fragment format, for improved compatibility with existing reagents, assays and techniques. (1)
Assay Types
Families
- Druggable Genome (35022)
- Transmembrane (10695)
- Transcription Factors (10267)
- Secreted Protein (5349)
- ES Cell Differentiation/IPS (4681)
- Protein Kinase (4001)
- Protease (2702)
- Stem cell - Pluripotency (2316)
- Adult stem cells (1216)
- Nuclear Hormone Receptor (905)
- Embryonic stem cells (792)
- Phosphatase (641)
- Cancer stem cells (535)
- Induced pluripotent stem cells (426)
- Stem cell relevant signaling - DSL/Notch pathway (365)
- Stem cell relevant signaling - JAK/STAT signaling pathway (297)
- P450 (291)
- Ion Channels: Other (288)
- Stem cell relevant signaling - TGFb/BMP signaling pathway (148)
- GPCR (122)
- Stem cell relevant signaling - Wnt Signaling pathway (55)
- Ion Channels: Potassium (45)
- Ion Channels: Transient receptor potential (32)
- Ion Channels: Cys-loop Receptors (28)
- Ion Channels: Sodium (8)
- Ion Channels: Glutamate Receptors (2)
- Ion Channels: Calcium (1)
- Ion Channels: Cyclic nucleotide gated (1)
Pathways
- Metabolic pathways (5975)
- Pathways in cancer (4348)
- MAPK signaling pathway (2887)
- Focal adhesion (2173)
- Prostate cancer (2092)
- T cell receptor signaling pathway (1831)
- Cell adhesion molecules (CAMs) (1803)
- Neurotrophin signaling pathway (1774)
- Colorectal cancer (1771)
- Melanoma (1711)
- Toll-like receptor signaling pathway (1687)
- Cytokine-cytokine receptor interaction (1634)
- Pancreatic cancer (1610)
- Glioma (1582)
- Bladder cancer (1574)
- ErbB signaling pathway (1561)
- Chronic myeloid leukemia (1526)
- Cell cycle (1484)
- Non-small cell lung cancer (1476)
- Progesterone-mediated oocyte maturation (1463)
- Endometrial cancer (1447)
- Regulation of actin cytoskeleton (1426)
- B cell receptor signaling pathway (1358)
- Insulin signaling pathway (1344)
- Hematopoietic cell lineage (1314)
- GnRH signaling pathway (1245)
- Fc epsilon RI signaling pathway (1219)
- Endocytosis (1213)
- Jak-STAT signaling pathway (1169)
- Renal cell carcinoma (1151)
- Apoptosis (1146)
- Acute myeloid leukemia (1103)
- p53 signaling pathway (1094)
- Wnt signaling pathway (1048)
- Purine metabolism (1039)
- Natural killer cell mediated cytotoxicity (1036)
- Leukocyte transendothelial migration (1008)
- VEGF signaling pathway (1003)
- Chemokine signaling pathway (1002)
- Small cell lung cancer (975)
- Thyroid cancer (955)
- Alzheimer's disease (932)
- Fc gamma R-mediated phagocytosis (913)
- Gap junction (911)
- Ubiquitin mediated proteolysis (906)
- Oocyte meiosis (878)
- Pyrimidine metabolism (870)
- Amyotrophic lateral sclerosis (ALS) (868)
- Huntington's disease (822)
- Adherens junction (820)
- Melanogenesis (762)
- Epithelial cell signaling in Helicobacter pylori infection (748)
- Adipocytokine signaling pathway (697)
- Type II diabetes mellitus (673)
- mTOR signaling pathway (673)
- Long-term depression (654)
- Basal cell carcinoma (631)
- Calcium signaling pathway (627)
- Long-term potentiation (622)
- Complement and coagulation cascades (621)
- Glycolysis / Gluconeogenesis (608)
- Axon guidance (604)
- Primary immunodeficiency (590)
- Tight junction (564)
- Antigen processing and presentation (560)
- Vascular smooth muscle contraction (559)
- Arginine and proline metabolism (558)
- NOD-like receptor signaling pathway (552)
- Systemic lupus erythematosus (545)
- RIG-I-like receptor signaling pathway (542)
- Pathogenic Escherichia coli infection (533)
- Parkinson's disease (520)
- Nucleotide excision repair (509)
- Prion diseases (507)
- Valine (473)
- Lysosome (472)
- leucine and isoleucine degradation (462)
- Dorso-ventral axis formation (455)
- TGF-beta signaling pathway (455)
- Hedgehog signaling pathway (453)
- Oxidative phosphorylation (439)
- Viral myocarditis (425)
- Proteasome (416)
- Autoimmune thyroid disease (397)
- Type I diabetes mellitus (390)
- Tryptophan metabolism (389)
- Glycerolipid metabolism (387)
- PPAR signaling pathway (380)
- Lysine degradation (378)
- Cytosolic DNA-sensing pathway (372)
- RNA degradation (367)
- Allograft rejection (360)
- Propanoate metabolism (355)
- Drug metabolism - cytochrome P450 (354)
- Phosphatidylinositol signaling system (353)
- Spliceosome (349)
- Pyruvate metabolism (341)
- Arachidonic acid metabolism (339)
- Fatty acid metabolism (338)
- Graft-versus-host disease (336)
- Metabolism of xenobiotics by cytochrome P450 (334)
- One carbon pool by folate (332)
- Hypertrophic cardiomyopathy (HCM) (319)
- Inositol phosphate metabolism (316)
- Histidine metabolism (314)
- Alanine (310)
- aspartate and glutamate metabolism (310)
- ECM-receptor interaction (304)
- Dilated cardiomyopathy (302)
- Tyrosine metabolism (302)
- DNA replication (293)
- Glutathione metabolism (291)
- Mismatch repair (289)
- Butanoate metabolism (277)
- Notch signaling pathway (277)
- Neuroactive ligand-receptor interaction (274)
- Arrhythmogenic right ventricular cardiomyopathy (ARVC) (259)
- Base excision repair (259)
- beta-Alanine metabolism (257)
- Glycine (254)
- serine and threonine metabolism (254)
- Drug metabolism - other enzymes (226)
- Renin-angiotensin system (218)
- Vibrio cholerae infection (217)
- Fructose and mannose metabolism (206)
- Retinol metabolism (204)
- Circadian rhythm - mammal (201)
- Maturity onset diabetes of the young (200)
- Amino sugar and nucleotide sugar metabolism (198)
- Homologous recombination (198)
- ABC transporters (196)
- Starch and sucrose metabolism (190)
- Cysteine and methionine metabolism (189)
- Cardiac muscle contraction (182)
- Linoleic acid metabolism (167)
- SNARE interactions in vesicular transport (162)
- Nicotinate and nicotinamide metabolism (159)
- Pentose phosphate pathway (157)
- Citrate cycle (TCA cycle) (142)
- Asthma (140)
- Terpenoid backbone biosynthesis (140)
- Porphyrin and chlorophyll metabolism (135)
- Glycerophospholipid metabolism (133)
- RNA polymerase (133)
- Sphingolipid metabolism (130)
- Aminoacyl-tRNA biosynthesis (122)
- Folate biosynthesis (119)
- Regulation of autophagy (119)
- Ribosome (119)
- Other glycan degradation (110)
- Ascorbate and aldarate metabolism (109)
- Fatty acid elongation in mitochondria (108)
- Caffeine metabolism (106)
- Methane metabolism (106)
- Sulfur metabolism (106)
- Galactose metabolism (105)
- N-Glycan biosynthesis (100)
- Nitrogen metabolism (95)
- Non-homologous end-joining (88)
- Primary bile acid biosynthesis (88)
- Glyoxylate and dicarboxylate metabolism (83)
- Basal transcription factors (78)
- Selenoamino acid metabolism (75)
- Phenylalanine metabolism (73)
- Synthesis and degradation of ketone bodies (71)
- Ether lipid metabolism (70)
- Thiamine metabolism (70)
- Androgen and estrogen metabolism (66)
- Olfactory transduction (66)
- Cyanoamino acid metabolism (65)
- Glycosaminoglycan degradation (55)
- Limonene and pinene degradation (55)
- Taste transduction (55)
- Pantothenate and CoA biosynthesis (40)
- Biosynthesis of unsaturated fatty acids (36)
- C21-Steroid hormone metabolism (35)
- Fatty acid biosynthesis (33)
- Keratan sulfate biosynthesis (30)
- Vitamin B6 metabolism (30)
- alpha-Linolenic acid metabolism (30)
- Riboflavin metabolism (29)
- Pentose and glucuronate interconversions (28)
- Glycosphingolipid biosynthesis - ganglio series (25)
- Glycosphingolipid biosynthesis - lacto and neolacto series (25)
- Glycosphingolipid biosynthesis - globo series (20)
- leucine and isoleucine biosynthesis (16)
- D-Glutamine and D-glutamate metabolism (15)
- Taurine and hypotaurine metabolism (15)
- Phenylalanine (11)
- Steroid biosynthesis (11)
- tyrosine and tryptophan biosynthesis (11)
- O-Glycan biosynthesis (10)
- Protein export (10)
- Biotin metabolism (5)
- Ubiquinone and other terpenoid-quinone biosynthesis (5)